Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer

Raffaele Califano, Keith Kerr, Robert David Morgan, Giuseppe Lo Russo, Marina Garassino, Floriana Morgillo, Antonio Rossi

Research output: Contribution to journalReview articlepeer-review


Despite better understanding of it’s molecular biology, non-small cell lung cancer (NSCLC) remains a challenging disease to treat. Unfortunately, treatment options are still very limited and prognosis for advanced disease is poor. Immune surveillance plays a crucial role in a host’s defence against tumour cells, and this is particular relevant for lung cancer due to it’s high somatic mutational load, which increases the chances for the immune system to recognize cancer cells as ‘non-self’. Novel immunotherapies are emerging as an effective treatment for this disease. In this review, we present the data on immune checkpoint inhibitors for NSCLC, describing their mechanism of action, data efficacy from recent clinical trials, and strategies to select patients more likely to benefit from these agents.

Original languageEnglish
Article number59
JournalCurrent Oncology Reports
Issue number9
Publication statusPublished - Sep 1 2016


  • Atezolizumab
  • CTLA-4
  • Durvalumab
  • Immune checkpoint
  • Nivolumab
  • Non-small cell lung cancer
  • PD-1
  • PD-L1
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this